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Cancer therapy often relies on the combined action of different molecules to overcome drug resistance
and enhance patient outcome. Combined strategies relying on molecules with different pharmacokinetics
often fail due to the lack of concomitant tumor accumulation and, thus, to the loss of synergistic effect.
Due to their ability to enhance treatment efficiency, improve drug pharmacokinetics, and reduce adverse
effects, polymer nanoparticles (PNPs) have been widely investigated as co-delivery vehicles for cancer
therapies. However, co-encapsulation of different drugs and probes in PNPs requires a flexible polymer
platform and a tailored particle design, in which both the bulk and surface properties of the carriers
are carefully controlled. In this work, we propose a core-shell PNP design based on a polyurethane
(PUR) core and a phospholipid external surface. The modulation of the hydrophilic/hydrophobic balance
of the PUR core enhanced the encapsulation of two chemotherapeutics with dramatically different water
solubility (Doxorubicin hydrochloride, DOXO and Docetaxel, DCTXL) and of Iron Oxide Nanoparticles for
MRI imaging. The outer shell remained unchanged among the platforms, resulting in un-modified cellular
uptake and in vivo biodistribution. We demonstrate that the choice of PUR core allowed a high entrap-
ment efficiency of all drugs, superior or comparable to previously reported results, and that higher core
hydrophilicity enhances the loading efficiency of the hydrophilic DOXO and the MRI contrast effect.
Moreover, we show that changing the PUR core did not alter the surface properties of the carriers, since
all particles showed a similar behavior in terms of cell internalization and in vivo biodistribution. We also
show that PUR PNPs have high passive tumor accumulation and that they can efficient co-deliver the two
drugs to the tumor, reaching an 11-fold higher DOXO/DCTXL ratio in tumor as compared to free drugs.
Statement of Significance
Exploiting the synergistic action of multiple chemotherapeutics is a promising strategy to improve the
outcome of cancer patients, as different agents can simultaneously engage different features of tumor
cells and/or their microenvironment. Unfortunately, the choice is limited to drugs with similar pharma-
cokinetics that can concomitantly accumulate in tumors. To expand the spectrum of agents that can be
delivered in combination, we propose a multi-compartmental core-shell nanoparticles approach, in
which the core is made of biomaterials with high affinity for drugs of different physical properties. We
successfully co-encapsulated Doxorubicin Hydrochloride, Docetaxel, and contrast agents and achieved
a significantly higher concomitant accumulation in tumor versus free drugs, demonstrating that nanopar-
ticles can improve synergistic cancer chemotherapy.
 2018 Acta Materialia Inc. Published by Elsevier Ltd. This is an open access article under the CCBY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Schematic representation of nanoparticles prepared with polyurethanes
with a different hydrophilic/hydrophobic balance. The lipid shell is composed by a
combination of two different phospholipids: L-a-phosphatidylglycerol (EGG-PG)
and 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[amino(polyethylenegly-
col)-2000] (DSPE-PEG).
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Efficient cancer treatment requires the drug to be delivered in
the right time and at the right place to maximize efficacy and min-
imize off-target side effects [1]. Because of the ability of cancer
cells to become resistant to treatments through the acquisition of
sequential mutations, the synergistic action of multiple drugs is
often manipulated to improve the therapeutic outcome of cancer
patients. Such combined strategies heavily rely on different drugs
reaching the same target at the same time, posing the issue of their
co-localization at the tumor site [2]. Indeed, different molecules
may not reach the tumor concomitantly due to their different
physical/chemical properties, administration routes and pharma-
cokinetics, resulting in the loss of synergistic effect [3,4].
Nanotechnology has provided several platforms designed to
package different molecules and/or imaging probes in an all-in-
one system in the attempt to enhance their co-delivery to the
tumor area [5–7]. Among them, polymer nanoparticles (PNPs) have
emerged as powerful tools, in virtue of their low toxicity profile,
enhanced tumor accumulation through passive and active target-
ing mechanisms, reduced renal clearance, and ability to co-host
multiple drugs [6,8]. For instance, Blanco and co-workers demon-
strated that drug co-encapsulation is a key factor to exploit syn-
ergy in vivo. They achieved a significantly higher reduction of
tumor volume when using Poly(e-caprolactone) (PCL) nanoparti-
cles to co-deliver Rapamycin and Paclitaxel to breast cancer as
compared to single-agent platforms [3]. Stigliano et al. also
enhanced the effect of Docetaxel by co-loading this drug and the
chemo-sensitizer Curcumin into poly(D,L) lactide-co-glycolide
(PLGA) nanoparticles [9]. The above studies demonstrate that
hydrophobic polymer matrices are powerful tools to synergize
hydrophobic drugs with high entrapment efficiency. Nevertheless,
concomitant chemotherapy with agents of different chemical/
physical properties remains a challenge as it requires to design bio-
materials with high affinity for both drugs.
In this work we exploit the versatile chemistry of polyurethanes
(PURs) to synthesize three polymers with modulated hydrophilic/
hydrophobic balance, achieved by inserting randomly-distributed
hydrophobic (PCL) and hydrophilic (PEG) domains at different
ratios [10–13]. Our previous papers, demonstrated that PURs are
promising candidates for the encapsulation of hydrophobic drugs.
For instance we showed that these polymers have a 3 fold-higher
Paclitaxel encapsulation efficiency as compared to polyester
nanoparticles and are able to sustain drug release for a longer per-
iod of time [11].
Here we investigated the effect of the PUR core composition on
the co-encapsulation of three agents: two potent chemotherapeu-
tics with different water solubility and biodistribution profiles (i.e.
Docetaxel and Doxorubicin Hydrochloride) and Superparamag-
netic Iron Oxide nanoparticles (SPIOs) for magnetic resonance
imaging (MRI). [14–16]. Because the use of different polymers
may modify the surface properties of PNPs, and in turn affect their
biodistribution and clearance, we opted for a core-shell design to
exploit the polymer properties only for the purpose of maximizing
payload encapsulation without altering the surface compartment
and, consequently, maintaining the same in vivo biodistribution
[17–19]. The schematic representation of the PUR PNPs is reported
in Fig. 1: all particles have the same phospholipid outer shell and a
different PUR core with modulated hydrophilic/hydrophobic
balance, obtained by varying the ratio between hydrophilic and
hydrophobic blocks in the PUR composition. We also investigated
the possibility of combining different imaging modalities such as
photo acoustic imaging (PAI) and MRI in the same platform, by
coupling a near infrared (NIR) dye to the amine-terminated PEG
chains on the phospholipid outer compartment to merge theanatomical, morpho-functional and metabolic information of PAI,
with the depth of investigation achievable with MRI for a more
comprehensive diagnosis [20–23].
We show that the hydrophilic/hydrophobic balance within the
PUR core affects the encapsulation and release of the hydrophilic
Doxorubicin HC, while plays a minor role on the release kinetics
of Docetaxel. It also strongly influences the entrapment of SPIOs
and, consequently the MRI contrast enhancement. In addition, we
demonstrate that the core shell approach allows modulation of
the core properties, while un-altering the surface and thus
maintaining the same cell internalization, in vivo biodistribution
profile and PAI performances. Moreover, we tested the best-
performing particles in tumor-bearing mice obtaining a high
passive tumor accumulation, where up to 30% of the circulating
particles accumulate in the tumor after 24 h. The co-loaded plat-
form successfully delivered the two drugs to the tumor, achieving
a 17-fold and a 1.6-fold higher drug accumulation for Doxorubicin
HC and Docetaxel respectively, as compared to the free-drug
combination.2. Materials and methods
2.1. Materials
For PUR synthesis: Poly(e-caprolactone)-diol (PCL-diol
(2,000 g/mol), Poly(ethylenglicole) (PEG (2,000 g/mol), n-BOC
Serinol, Dibutyl Dilaurate (DBTL), and 1,6 Hexamethylene diiso-
cyanate (HDI) were purchased from Sigma Aldrich (Italy). L-a-
phosphatidylglycerol (EGG-PG), 1,2-distearoyl-sn-glycero-3-
phosphoethanolamine-N-[amino(polyethyleneglycol)-2000] (DSPE-
PEG-NH2) and L-a-Phosphatidylethanolamine-N-(lissamine-rhoda
mineB-sulfonyl) (Egg-Liss-Rhod PE) were purchased from Avanti
Polar Lipids. The NIR dye CW800-NHS ester was purchased from
Li-cor. SPIOs (5 nm), Doxorubicin Hydrochloride, Docetaxel and
all cell culture reagents were purchased from Sigma Aldrich (Italy).
All solvents were of analytical grade. Balb/c mice were purchased
from Charles River laboratories (USA). Animal studies were con-
ducted under the approval of the Animal Care and Use Committee
at the Houston Methodist Research Institute, in adherence to the
National Institutes of Health Guide for the Care and Use of Labora-
tory Animals.2.2. Polyurethane synthesis
PURs synthesis was carried out following a two-step synthesis
procedure in inert atmosphere, by dissolving PCL-diol (for
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(for mixed PCL-PEG polyurethanes, PU70 and PU80) in anhydrous
1,2-dichloroethane (DCE) (20% w/v) [11]. Diisocyanate (HDI) was
added at 2:1 M ratio and the reaction was allowed to proceed for
150 min at 85 C to obtain a pre-polymer (DBTL was used in cat-
alytic amount), followed by n-BOC serinol chain extender addition
(1:1 M ratio) at room temperature. The chain extension reaction
was stopped after 16 h by addition of methanol, the polymer was
precipitated in petroleum ether, and purified by precipitation in
diethyl-ether/methanol (95:5) to remove low molecular weight
impurities and residual catalyst. Size exclusion chromatography
(SEC, Agilent Technologies 1200 Series, USA) was used to deter-
mine PUR molecular weight using a Refractive Index detector
and two Waters Styragel columns (HT2 and HT4) conditioned at
35 C. Tetrahydrofuran was used as mobile phase at a flow rate
of 0.5 mL/min with an injection volume of 20 lL. Attenuated Total
Reflectance Fourier Transform Infrared Spectroscopy (ATR-FT-IR)
was performed using a Perkin Elmer Spectrum 100 equipped with
an ATR accessory (UATR KRS5) with diamond crystal.
2.3. Preparation of hybrid PUR/lipid nanoparticles
Nanoparticles were prepared by a nanoprecipitation/self-assem
bly method. Doxorubicin HC (DOXO, 50 mg), SPIOs (100 mg) and
PURs were dissolved in chloroform and the solvent was allowed
to completely evaporate under nitrogen flow. The polymer/
DOXO/SPIOs precipitate was solubilized in a 1 mL solution of Doc-
etaxel (DCTXL, 100 mg) in acetonitrile. The solution was then
dropped into 2 mL of water containing 200 lg of Egg-PG and
240 lg of DSPE-PEG-NH2 and 100 lg of CW800-DSPE-PEG at
60 C. Following addition of DI water (1 mL) the particle suspen-
sion was centrifuged at 3200 rpm and washed twice using a solu-
tion concentrator with a molecular-weight cutoff of 10 kDa. For
cell internalization studies, drug-free Rhodamine-labeled nanopar-
ticles were prepared by adding 5 mg of Egg Liss Rhod PE in water
during nanoparticles preparation.
2.4. Physico-chemical characterization of nanoparticles
The particle size and size distribution were analyzed using
Dynamic Laser light Scattering (DLS) (Malvern, Zetasizer Nano
S90) on three independent PNPs batches. For morphological analy-
sis, transmission electron microscopy (TEM) images were taken at
the Baylor College of Medicine Cryo-Electron Microscopy Core
Facility (Texas Medical Center, Houston, TX). 3 ml of sample were
loaded onto Quantifoil holey carbon grids (Quantifoil Micro Tools
GmbH, Jena, Germany) and imaged with a 200kV JEOL Model
2200 Electron Microscope (JEOL Ltd, Japan) outfitted with an in-
column Energy Filter. Images were captured using a Direct Electron
DE20 direct detection device (Direct Electron, San Diego, CA) and
the image capturing software SerialEM (Boulder, CO). Stability of
PNPs was assessed in PBS at 37 C over a period of 7 days, by daily
measurements of size distribution by DLS.
2.5. Drug loading and release quantification
DCTXL loading and release were measured by HPLC (Thermo-
Fisher, Ultimate 3000) equipped with a C18 column and UV detec-
tor at 227 nm, with 1 mL/min flow rate using acetonitrile and
water (50:50) as mobile phase. DOXO was quantified by UV spec-
troscopy (Perkin Elmer, Lambda 365) at 480 nm in water/acetoni-
trile (50:50). For drug release, PNPs (1 mg/ml) were suspended in
phosphate buffer (PBS, pH 7.4). At predetermined time intervals,
the suspension was centrifuged and the supernatant was collected
and analyzed by HPLC followed by UV analysis.Encapsulation Efficiency (EE) was determined according to the
following equation (Eq. (1)):
EE ¼ D=D  100 ð1Þ
where D* is the amount of drug initially supplied, and D is the
amount of the drug quantified in the batch. Drug release data were
fitted according to the Korsmeyer-Peppas equation using the Sig-
maPlot software (Systat Software Inc.) to calculate the equation
parameters.
2.6. SPIOs loading
Samples were acid-digested in a Start D microwave-assisted
digestion system (Milestone – Sorisole, BG, Italy). An aliquot of
1 mg of each sample was weighed and put in a PTFE vessel with
4 mL of 69% nitric acid and 4 mL of ultrapure water (Merck Milli-
pore, Darmstadt, Germany). Iron content analysis was performed
with a Thermo Scientific X Series 2 ICP-MS (Thermo Fisher Scien-
tific –Waltham, MA, USA) equipped with a PFAmicro-flow concen-
tric nebulizer. Analyses were carried out in CCT-KED mode.
Quantitative analysis were performed by means of calibration
standard solutions in the range of 0.1–100.0 lg/L. Iron 1000 lg/
mL stock solution was purchased by Inorganic Ventures (Chris-
tiansburg, VA, USA). Instrumental data were elaborated by Plasma-
Lab software, version 2.6.1.335.
2.7. Cell internalization and cytotoxicity studies
U-87 MG cells (Sigma Aldrich) were maintained in eMEM, sup-
plemented with 10% FBS and 1% Penicillin/streptomycin. Cells
were plated at 10,000 cells/well and cultured for 24 h. The medium
was then substituted with 200 mL of PNPs suspension (empty
nanoparticles, single drug-loaded PNPs, dual drug loaded PNPs
and free drugs) in complete medium at different concentration
and incubated for 24 h and 48 h. Cell viability was determined by
Calcein Am assay, according to the manufacturer’s instructions.
Cell internalization of rhodamine-labelled empty PNPs was visual-
ized by Fluo ViewTM 1000 confocal microscope (Nikon). Briefly
U87 cells were incubated with PNPs (0.5 mg/mL) for 2 h, fixed in
formalin for 20 min, washed three times with sterile PBS and
stained by DAPI to visualize the nuclei. For the quantification of
particle internalization, cells were washed 3 times with sterile
PBS to remove particles that were not internalized, detached from
the plate, centrifuged and washed 2 extra times with sterile PBS.
Untreated cells were used as controls. Cells were analyzed by BD
Accuri C6-Plus flow cytometer, using R-phycoerythrin (PE) laser
(Ex/Em. 496/578) and recording 80.000 events per sample (n = 3).
2.8. Relaxometric analysis
In vitro T1- and T2-weighted MR relaxation studies were per-
formed in 2% agar phantoms, using a clinical 3T scanner (GE Excite
HDXt from GE Healthcare, USA). The longitudinal (T1) relaxation
time was obtained using inversion recovery pulse sequence (Repe-
tition Time (TR) = 5000 ms; field of view (FOV) = 16  16 cm; num-
ber of excitations = 2, 224x224; Echo Time (TE) = 8.52 ms;
Inversion times (TI) = 50, 100, 300, 500, 700, 900, 1100, 1300,
1500, 1700, 1900, 2100, 2300 ms), while the transverse (T2) relax-
ation time was measured using a T2 map Spin Echo pulse sequence
(acquisition parameters: TR = 5000 ms; FOV = 16  16 cm; number
of excitations = 2, 224x224; TE = 7, 14, 21, 28, 35, 42, 49, 56, 63, 70,
77, 84, 91, 100, 107, 114 ms) at different PNPs concentrations
(0.14; 0.07; 0.03 mM equivalent Fe content). Transverse relaxivity
(r2) and longitudinal relaxivity (r1) values were estimated by the
slope of the regression curve, according to the following equation
(Eq. (3)):
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where Ri (= 1/Ti) is the relaxation rate and C is the nanoparticles
concentration.
2.9. Photoacoustic imaging
Photoacoustic (PA) and ultrasound (US) measurements were
performed with VevoLAZR system (FUIJIFILM VisualSonics Inc.).
Samples were excited with a Nd:YAG laser (6–8 ns pulse width,
20 Hz) with an optical parametric oscillator from 680 to 950 nm.
The laser illumination is transferred to the sample by a PA-US
probe consisting of a Piezoelectric Linear Array (PLA) echography
transducer (13–24 MHz with FOV of 23  30 mm). The PNPs
behavior was studied in in vitro and ex vivo setups. The in vitro
PA custom-made phantom is composed by a cubic polypropylene
(PP) box and PE tubes loaded with the PNPs. We tested 3 PNPs con-
centrations in PBS (0.75 mg/mL; 1.5 mg/mL; 3.0 mg/mL). PBS alone
was used as blank. For the ex vivo setup, tissue samples of approx.
30  15  10 mm were placed inside the PP box, covered with
agarose (1% w/v) at 36 C, and sonicated for 15 min. Before the
PA acquisitions, 150 mL from PNPs stock solution (3 mg/mL) were
injected, the system was filled with water and analyzed to evaluate
photo-stability (PHS) and spectral PA response. The PA values were
calculated into selected regions of interest (ROI) of the same size.
The Spectral PA response analysis (PAS) was performed using a
laser stimulation (2 nm step, 26 mJ of maximum energy peak) in
the range 680–950 nm. The PHS was evaluated over 1 min (300
laser shots) under pulsed irradiation at 770 nm. The stability (i.e.
the PA signal intensity over time) was studied under continuous
laser stimulation by calculating the percentage difference between
the value acquired during the first and the last 3 s of PHS acquisi-
tions. The contrast-to-noise ratio (CNR) and Contrast were assessed
in post processing [24]. Details for the calculation of these param-
eters are reported in the supplementary information paragraph.
2.10. Biodistribution analysis
For biodistribution analysis, CW-800 labelled nanoparticles
were intravenously injected and mice were sacrificed at different
time-points post-injection (3 h, 6 h, 24 h; 3 mice/group) through
cardiac puncture. Organs were harvested and analyzed by IVIS
imaging to evaluate the qualitative dynamics of uptake and clear-
ance. Fluorescence in organs and blood was quantified by measur-
ing the fluorescence spectra of homogenized organs using a
Synergy H4 Hybrid Microplate Reader (BioTek) (Excitation Wave-
length 745 nm, Emission Wavelength 780 nm). Collected organs
were homogenized with a T25 Digital Ultra Turrax Homogenizer
(Ika; 25  103 rpm; 1 min/organ) in PBS. Plasma was separated
from whole blood by centrifugation (10 min, 3000g). Organ homo-
genates from pristine mice were used to normalize the results.
Biodistribution was also evaluated in tumor-bearing mice for the
best performing PNP platform. Briefly, Balb/C mice (3 groups of 3
mice each) were sub-cutaneous injected with luciferase-
transfected 4T1 breast cancer cells (100.000 cells). Once the tumors
reached a similar luminescence signal (detected by IVIS imaging
and reported as supplementary Fig. 1), mice were injected i.v. withTable 1
Molecular weight and polydispersity (D) of PURs. Size, PDI and Zeta potential or PUR PNP
Material PUR composition PUR characterization
PCL (%) PEG (%) Mw (Da)
PU 70 70 30 4.6 x 10^4
PU 80 80 20 5.2 x 10^4
PU 100 100 0 4.6 x 10^4CW-800-labelled empty PU80 PNPs (group 1), co-loaded PU80
PNPs (group 2), and a combination of the two un-encapsulated
drugs (group 3) at a final concentration of 3 mg/kg for both drugs.
Mice from group 1 were imaged after 3 h, 6 h and 24 h by live
imaging system IVIS and PNPs distribution was evaluated at the
24 h time point as described above in blood, organs, and tumor
explants. Tumor explants from group 2 and group 3 mice were
homogenized, the drugs were extracted form tissue homogenates
and quantified by fluorescence reading (Ex/Em. 470/550) for Dox-
orubicin HC and by HPLC at 227 nm for DCTXL [25,26].2.11. Statistical analysis
Results are expressed as mean ± standard deviation calculated
using Microsoft Excel (Redmond, WA, USA) software. Statistical
analysis was performed using Prism GraphPad software. One-
way ANOVA followed by the post hoc analysis (Tukey) was used
to compare the results. A p value of less than 0.05 was considered
as statistically significant.3. Results
3.1. Characterization of nanoparticles – surface properties
PURs with the desired structure were successfully obtained, as
demonstrated by ATR-FTIR spectra (supplementary Fig. 2a) that
show the stretching vibration of the –NH groups (3300–
3400 cm1), the CH2 groups (2850–2970 cm1), and the stretching
vibrations of the –C–O–C– and the carbonyl groups of the PCL seg-
ments (1190 cm1 and 1723 cm1). For PEG-containing PURs, an
additional signal at 1110 cm1 associated with the stretching of –
C–O–C– of the ether groups in the PEG segments was detected.
All PURs have similar molecular weights, ranging from 4.6*10^4
to 5.3*10^4, with a low dispersity, as shown in Table 1 and by
SEC traces, reported in supplementary Fig. 2b.
PNPs with small size and with the desired core-shell structure
were obtained by nano precipitation self-assembly method,
regardless of the choice of the PUR core, as confirmed by TEM
(Fig. 2a) and by DLS measurements (Table 1). Size, PDI and zeta
potential were similar among the tested platforms, and spherical
PNPs with small diameters ranging from 95 to 140 nm, depending
on the polymer composition, and a negative surface charge were
obtained.
The presence of hydrophilic blocks in the polyurethane soft seg-
ment resulted in enhanced polydispersity index (PDI) and in
reduced size of the PNPs prepared by the nanoprecipitation self-
assembly method. We assumed this was due to the affinity
between PEG and water that reduced the interaction between
the polymer core and the stabilizing phospholipid outer shell dur-
ing nanoprecipitation. For instance, we also synthesized PURs with
a 40% ratio between PEG and PCL (PU60) but could not achieve a
stable particle structure with this polymer, as demonstrated by
the high PDI and by the biphasic DLS profile of PU 60 PNPs shown
in supplementary Fig. 3. For this reason, a maximum amount of
PEG of 30% in the PUR composition could be inserted to obtains.
PUR PNPs characterization
D Size (nm) PDI Z-Potential (mV)
1.44 95 ± 6 0.3 ± 0.003 57 ± 0.7
1.42 101 ± 3 0.3 ± 0.006 76 ± 0.7
1.28 143 ± 5 0.2 ± 0.003 73 ± 2.2
Fig. 2. a) TEM analysis of PU100, PU80, and PU70 PNPs (scale bars represent 500 nm); b) PNPs stability curve over 7 days of incubation in saline, evaluated as a daily
measurement of size (black curves) and PDI (red curves). (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this
article.)
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method.
All PUR PNPS showed good stability in normal saline (Fig. 2b) as
demonstrated by the unaltered size and PDI over the tested period
of 7 days, and did not elicit evident signs of toxicity on in vitro cell
cultures up to a concentration of 1 mg/mL (supplementary Fig. 4c).
We also evaluated the extent of rhodamine-labelled PNPs internal-
ization by cancer cells in vitro, which is known to be dependent on
the surface properties of the carriers. Rhodamine-labelled PNPs
showed a similar internalization profile (Fig. 3a) regardless of the
PUR composition. The particles were quickly internalized by cancer
cells, due to the cell membrane-friendly phospholipid shell, and
appeared to be mainly localized in the cytoplasm, as evidenced
by the red fluorescence of rhodamine around the nuclei. Z-stack
images, taken at higher magnifications (supplementary Fig. 4b)
confirmed the location of the particles inside the cells. The uptake
of nanoparticles was high for all platforms, ranging from 64 ± 4%
for PU100 to 72 ± 1% for PU70 PNPs (Fig. 3b), confirming similar
uptake profiles among carriers.
Because stability, toxicity and cell uptake are mainly surface-
dependent properties, the above results suggest that the surface
of PNPs was not altered by the use of different PUR cores.
To further support this statement we also evaluated the biodis-
tribution profiles in vivo on Balb/c mice after 3 h, 6 h, and 24 h
from tail vein injection (Fig. 4).
As expected, all particles accumulated preferentially in the liver
and kidneys, through which they are excreted and were eliminated
from circulation within 24 h from injection, as shown by the sharp
decrease in fluorescence concentration in the blood at the 24 h
time point [27,28]. Because all platforms share similar surface
charge, surface composition, stability and size, no significant differ-
ence was observed in biodistribution profiles among PUR PNPs.
These results support our hypothesis that particles of similar
size with the same surface compartment, behave similarly
in vitro and in vivo.
3.2. Characterization of nanoparticles – bulk properties
Properties that are dependent on the PUR composition, such as
drug entrapment efficiency, release profile and cytotoxicity, are
reported in Table 2 for single agent platforms (i.e. PUR PNPs loaded
with one agent at the time) and for co-loaded platforms (PUR PNPs
containing the three payloads). The presence of the hydrophilic
PEG domains clearly enhanced the encapsulation efficiency (EE)
of the hydrophilic DOXO (p = 0.0002).
In multiple-agent platforms DOXO encapsulation was signifi-
cantly higher (30%) for the hydrophilic PURs as compared to
the hydrophobic PU100 (20%) (p = 0.032 and p = 0.045 for PU70
vs PU100 and PU80 vs PU100, respectively). When compared to
other platforms for DOXO or DCTXL delivery, single-agent loaded
PUR PNPs displayed a 1.1–2.3 fold higher DOXO EE, and a 1.2–4.8fold higher DCTXL EE. Notably, when 3 agents were co-loaded in
PUR PNPs, the EE of the drugs was still higher than or comparable
to the EE values obtained in literature, thus confirming the poten-
tial of PUR PNPs as drug loading devices able to host multiple pay-
loads [9,29–31]. Fig. 5a shows the cumulative release profiles of
DOXO and DCTXL from PUR PNPs. As expected, the release of the
hydrophilic drug was fast from all platforms, given the high affinity
of the payload for the external aqueous environment, and was
completed after 48 h of incubation. DCTXL release profile was more
controlled over time for all 3 PNPs, with a slower release rate from
PU100 PNPs. The release kinetic of DCTXL was similar for all PNPs
(Fig. 5a) and characterized by a burst release in the first hours, fol-
lowed by a constant release probably due to diffusion of DCTXL
from PNPs and to a partial erosion of the particle. DCTXL-loaded-
PLA/PLGA-NPs prepared by Musumeci et al displayed a similar
biphasic release profile, but a much higher initial burst effect of
about 40% to 68% within the first sampling time (24 h) [31]. In
terms of in vitro cytotoxicity, all PUR PNPs showed similar results
(Fig. 5b). In vitro drug release curves were fitted according to the
Korsmeyer-Peppas model (Mt/M1 = Ktn) where Mt/M1 indicates
the fraction of drug released at time t, k is the release rate constant
and n is the release exponent, which is correlated with the drug
release mechanism [32]. The values of the constant k, summarized
in supplementary Fig. 5, are lower than 0.45 for all PUR PNPs,
which correspond to a Fickian diffusion mechanism.
Cytotoxicity graphs for free drugs and single agent-PNPs,
reported in supplementary Fig. 6, show that both drugs have strong
cytotoxic effect on U87 in vitro. After 48 h of incubation, the IC50
of free DCTXL and free DOXO were 3.13 mg/ml and 1.59 mg/ml,
respectively. Encapsulated DCTXL and DOXO maintained similar
IC50 values, ranging respectively from 5.19 mg/ml and 2.69 mg/ml
for PU100; 0.91 mg/ml and 1.31 mg/ml for PU80; and 4.78 mg/ml
and 1.88 mg/ml for PU70. The combined platforms showed IC50
as low as 1 mg/ml for combined drugs after 48 h of incubation.
No significant differences were observed among platforms, in
accordance with their similar release profiles.
The encapsulation efficiency of SPIOs did not vary significantly
among platforms, particularly when SPIOs were co-loaded with
DCTXL and DOXO (Table 2). These results indicate that the pres-
ence of PEG did not affect the entrapment efficiency of hydropho-
bic SPIOs, but affected the superparamagnetic behavior of PNPs.
Fig. 6a summarizes the relaxometric properties in terms of longitu-
dinal (r1) and transversal (r2) relaxivities. All platforms showed
high r2 values, ranging from 25.86 ± 13.02 (mM s)1 for PU70,
27.33 ± 8.58 (mM s)1 for PU80 and 20.98 ± 7.23 (mM s)1 for
PU100. Encapsulated SPIOs showed a typical superparamagnetic
behavior, which was not affected by the polymer coating [33].
The presence of PEG domains significantly affected the MRI con-
trast enhancement, confirming that hydrophilic coatings improve
the magnetic response of SPIOs (Fig. 6b) [34]. Indeed, proton relax-
ation of paramagnetic systems has been shown to depend mainly
Fig. 3. a) Internalization of PUR PNPs by U87 glioblastoma cancer cells in vitro. Rhodamine-labelled, drug-free PNPs appear in red, nuclei were stained with DAPI (scale bars
correspond to 50 mm); b) Quantification of cell internalization by flow cytometry. Green: percentage of rhodamine-positive cells, purple: percentage of negative cells. (For
interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
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Thus, for PU70 and PU80 PNPs that contain hydrophilic PEG
domains, interactions with water protons were favored.
On the other hand, the hydrophobic PU100 PNPs had lower
interaction between water protons and encapsulated SPIOs, result-
ing in a lower transversal response. The r2/r1 ratio of SPIOs-loaded
PNPs, which is a measure of the contrast-enhancement efficiency
of the system, was also dependent on the PEG content, ranging
from 27 ± 1 for PU 70, 26 ± 7 for PU 80, and 15 ± 6 for PU 100. Con-
sidering that commercial T2 contrast agents typically possess a r2/
r1 ratio in the range between 2 and 40, and that commercially-
available agents such as Resovist, Feridex and Combidex have ar2/r1 ratio <14.1, the values obtained for all PUR PNPs warrant their
further investigation as T2-contrast agents in MRI [36,37].
PA performance of PUR PNPs are summarized in Fig. 7 and in
Table 3. All PUR PNPs exhibit comparable PA spectra profiles and
signal intensities both in our in vitro (PE tubes) and ex vivo (tissue
phantoms) setups. The in vitro photostability (PHS) of the surface-
immobilized dye was very high for all tested PNP (supplementary
Fig. 7), while the dye alone showed high variability in signal inten-
sity over the tested period of time. PUR PNPs displayed a signifi-
cantly higher PA signal when compared to the semiconducting
self-assembled polymer-based nanoprobes developed by Xie and
coworkers and by Pu et al [38–40].
Fig. 5. Drug release profiles (a) and cytotoxicity profiles (b) of PUR PNPs.
Fig. 4. Biodistribution profile of PUR PNPs. Quantification of fluorescence in extracted organs at different time points (upper panel), and IVIS imaging of extracted organs (one
representative mouse per polyurethane for each time point).
Table 2
Encapsulation efficiency of PUR PNPs when used as multiple-agent loading platforms or as a single-agent loading platform. Physico-chemical characterizations of single-agent
loaded PUR PNPs are reported in supplementary Table 1.
Material Single-agent platforms Co-loaded platforms
EE Doxo (%) EE Dctxl (%) Fe [ppm] EE Doxo (%) EE Dctxl (%) Fe [ppm]
PU 70 45.2 ± 4.7 43.8 ± 6.2 4844 ± 737 31.0 ± 4.8 15.8 ± 0.5 4602 ± 203
PU 80 44.8 ± 1.3 48.2 ± 6.0 5545 ± 308 30.1 ± 3.5 17.5 ± 1.1 4671 ± 80
PU 100 22.3 ± 0.5 22.0 ± 2.7 7607 ± 1282 19.6 ± 3.2 13.2 ± 1.5 5860 ± 174
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Fig. 6. Relaxometric properties of PNPs. Transversal (r2) and longitudinal (r1) relaxivity for all platforms (a). Dose-dependent (mM Fe equivalent) contrast enhancement on
agar phantoms (b).
Fig. 7. PA properties of PNPs. a) 3D renders of PA-US distribution of different PNPs concentration at 770 nm loaded in PE tubes, b) Ex vivo phantom results: 3D render of PA
distribution of PNPs (600 mg/ml) perfusion inside the tissue of phantom after the injection, c) Spectra of CW-800 modified PNPs (600 mg/ml), measured in the in vitro set up
and in the ex vivo 3D phantom.
Table 3
PA performances derived from PUR PNPs after phantom and ex vivo tests.
Material In vitro Ex vivo
PA (770 nm) CNR Contrast PA CNR Contrast
PU 70 1.3 45.6 21.4 1.5 ± 0.2 30 9
PU 80 1.2 40.7 18.3 1.1 ± 0.1 76 11
PU 100 1.4 89.9 18.1 2.2 ± 0.1 67 16
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Given that all PNPs behaved similarly in terms of circulation
properties and cell internalization kinetics, we selected the best-performing PUR PNP (PU80) platform in terms of higher drug
entrapment efficiency, sustained release profile, MRI contrast
enhancement, and PA imaging performances and injected it into
tumor-bearing mice to investigate the passive tumor targeting
ability. Fig. 8a, and c show the biodistribution of PU80 PNPs in
tumor-bearing mice. After 24 h from the injection, a high PNP dose
accumulated in the tumor (5.1 ± 2.1% of the injected dose), while
7.5 ± 4.3% remained in the liver.
When loaded with DOXO and DCTXL, the particles significantly
enhanced drug co-delivery to tumor as compared to free drugs
(Fig. 8b). A 15-fold increase in tumor accumulation of DOXO vs free
drug was obtained with PNPs, while a 1.6-fold increase was
achieved for DCTXL. The ratio between DOXO and DCTX in tumor
Fig. 8. Biodistribution of PUR 80 PNPs after tail vein injection in tumor-bearing mice. a) Quantification of fluorescence in extracted organs after 24 h; b) drugs quantification
in the extracted tumors for nanoparticles-injected and free drugs-injected mice; c) in vivo circulation of nanoparticles imaged by IVIS system at different time points.
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than that achieved with free drugs.4. Discussion
Combination of chemotherapeutics is a valuable strategy to
improve patient outcome and to overcome drug resistance. Unfor-
tunately, different drugs may have different delivery routes and
chemical/physical properties, resulting in un-matching pharma-
cokinetics and tumor accumulation profiles and in the loss of the
synergistic effect [3]. Because of their ability to passively or
actively accumulate into tumors, polymer nanoparticles have been
proposed to package different molecules in a single polymer core
in order to enhance their co-delivery [6]. While co-encapsulation
of hydrophobic drugs has been achieved with success, the combi-
nation of hydrophilic and hydrophobic drugs remains an issue, as
it requires polymer platforms with high affinity for both molecules
[3,9].
In this work we used the tunable chemistry of poly(ester-ether)
urethanes (PURs) containing hydrophobic (PCL) and hydrophilic
(PEG) blocks at different ratio (100/0; 80/20 and 70/30) to increase
affinity for both, hydrophilic and hydrophobic drugs. We previ-
ously showed that PUR PNPs have higher entrapment efficiency
of hydrophobic drugs and display more sustained delivery as com-
pared to traditional polyester PNPs [11,41]. We have attributed
this high PUR/drug interaction to the semi-crystalline nature of
PURs and to the presence of amorphous domains in their
microstructure [42]. In this work we demonstrate that the inser-
tion of PEG blocks in the PUR soft segment composition results
in higher entrapment efficiency of DOXO, while DCTXL encapsula-
tion did not depend on the soft segment composition and remained
high among all tested platforms. When PUR PNPs were co-loaded
with 3 agents (2 drugs and SPIOs as MRI contrast agents), the EE
of the drugs was higher than or comparable to the EE values
obtained in literature for single-agent PNPs, thus confirming thepotential of PUR PNPs as drug loading devices able to host multiple
payloads. Yoo and co-workers reported DOXO-loaded polymeric
micelles with an EE of 20%, while Dessy et al obtained DOXO
EE in the range 23–26% using the poly(ether-ester-urethane)
nanoparticles [29,30]. For DCTXL, EE values ranging from 10 to
25% were reported by Musumeci et al. for PLA/PLGA-NPs, and by
Decuzzi and co-workers for PLGA PNPs [9,31]. The presence of
PEG also played a role in enhancing the MRI contrast enhancement,
in spite of similar SPIOs EE of the three PUR PNPs. This was attrib-
uted to the favored PUR matrix hydrations and to the consequent
interaction between entrapped SPIOs and water protons that has
been reported to enhance the contrast effect in MRI. We showed
that modulation of the polymer core properties is a promising
strategy to co-load drugs with different physical properties and
pharmacokinetics.
One other important issue in designing particles for drug deliv-
ery is the effect of the polymer matrix on the surface properties of
the carriers that strongly affect cell interaction, in vivo biodistribu-
tion and tumor accumulation of PNPs [17,18]. To reduce the effects
of the different polymer on the surface properties of the carriers,
we opted for a core/shell particle design, in which PURs constitute
the core and can be modified to favor entrapment of different
compounds, and the surface is conceived to remain un-altered
and is composed of a mixture of phospholipids and PEGylated
phospholipids.
Our results showed that this PNP design favors cell internaliza-
tion and results in similar biodistribution profiles. All particles
showed long circulation time, accumulated mainly in the liver
due the low blood velocity in this organs that favors PNPs uptake
by macrophages, and were excreted through the kidneys, as widely
reported for particles of this size and surface charge [27]. No signif-
icant differences in biodistribution or in vitro cell uptake were
observed among platforms, indicating that the surface properties
of the carriers remained un-altered. In tumor-bearing mice, PU80
PNPs showed high passive tumor accumulation, with more than
5 % of the 5 injected dose accumulating in tumors after 24 h.
350 C. Mattu et al. / Acta Biomaterialia 80 (2018) 341–351Moreover, PUR PNPs efficiently co-delivered the two drugs at the
target site. We observed a 15-fold increase in DOXO accumulation
in tumors as compared to free drug. Only a small amount of DOXO
was detected in tumors of mice treated with un-encapsulated
drugs, coherently with previous reports that indicate DOXO clear-
ance within few minutes from injection [15]. We also detected a
1.6 fold higher DCTXL content in tumor for encapsulated drugs as
compared to free drugs. The ratio between the two drugs delivered
through the co-loaded platform was 11-fold higher than that
obtained for free drugs, indicating that the proposed particle
design can improve drug accumulation and also can efficiently
co-localize chemotherapeutics with different pharmacokinetics.
5. Conclusions
In this work, PNPs were prepared using PURs containing differ-
ent percentages of hydrophilic domains (0%, 20% and 30%) as the
particle’s core, and a specific composition of phospholipids as the
outer shell. The versatility of the outer shell was also exploited
for photoacoustic/fluorescent imaging purposes, with high effi-
ciency. This approach resulted in good modulation of the drug
encapsulation efficiency without negatively influencing circulation
time, biodistribution, cellular uptake, and stability, which are
known surface-dependent properties. Efficient tumor co-
localization of drugs with different physical/chemical properties
was achieved through modulation of the hydrophilic/hydrophobic
balance of PURs. These findings evidence the advantages of using
tunable polymers for PNPs and suggest further investigation on
the use of tailor made PURs in nanomedicine.
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